Edison Initiates Coverage on Tonix Pharmaceuticals

News provided by

Apr 08, 2015, 11:05 ET

LONDON, April 8, 2015 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Tonix Pharmaceuticals

(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Highlights of the analysis on Tonix Pharmaceuticals by Edison's pharma & biotech analysts, Maxim Jacobs and Dr Mick Cooper, include:

Tonix is an emerging specialty pharmaceutical company focused on psychiatric and neurological disorders. TNX-102 SL for fibromyalgia is the most advanced, entering Phase III. It is also being developed for PTSD. TNX-201 is being developed for episodic tension-type headache (ETTH).

Tonix has a pipeline of three different programmes, all targeting large indications. The most advanced programme is TNX-102 SL for fibromyalgia. Although the Phase II BESTFIT trial missed the primary endpoint, the proposed Phase III study should have a higher chance of success, due to a much larger sample size and a previously met primary endpoint being used. The post-traumatic stress disorder (PTSD) and episodic tension-type headache programmes target areas with significant unmet medical needs. We value Tonix at $350m or $21.71 per basic share.

To download this report, please click here.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:
Maxim Jacobs
Edison Investment Research
+1-646-653-7027

Dr Mick Cooper
Edison Investment Research
+44-(0)20-3077-5734
[email protected]
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on: